Clinical Trial Update: A Trial of AVID200, a Transforming Growth Factor β (TGFβ) Inhibitor, in Patients Malignancies [Phase 1]

View source ↗

Summary

Phase 1 trial of AVID200, a Transforming Growth Factor β (TGFβ) inhibitor, in patients with malignant solid tumors has completed. Sponsored by Bristol-Myers Squ…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• AVID200

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Malignant Solid Tumor | Phase 1 | Status: COMPLETED